skip to Main Content
In mid-March, the FDA approved the postpartum depression drug brexanolone, providing an option to millions of women who suffer from postpartum depression. Brexanolone is the first federally-approved drug of its kind to be designed specifically to treat postpartum depression. The…
AZZLY joins the Behavioral Health Association of Providers (BHAP) in asking you to support the behavioral health industry by signing this petition. This petition will be delivered to President Trump, the Senate, and the House of Representatives and would urge…
If you’re reading this post, you likely already know the seriousness of the opioid epidemic currently in the United States. The opioid epidemic is the largest the U.S. has faced in decades, arguably since the emergence of AIDS. Opioid use…
In 2018, five drug distribution executives were summoned to testify before the House Energy and Commerce Committee oversight panel. The panel covered more than a dozen case studies, but one of the most striking was the case of Kermit, West…
This blog post references the 2019 Draft Report. Read it in full here. The public will have the opportunity to make comments on the Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations (Draft Report) before it…
Former Mississippi attorney general Mike Moore famously orchestrated a $250 billion settlement from major tobacco companies in the 1990s. Now he's back to take on the opioid industry. CBS covered Moore and his efforts in a Sunday, December 16, episode…
Meth is back. And it's surging faster than you might realize. While U.S. discussion and policy has focused on combating opioid addiction (the 70-bill Opioid Crisis Response Act was passed just this October), the methamphetamine crisis may have been returning…
Health and Human Services Secretary Alex Azar announced this November in a speech to the National Association of Medicaid Directors that the Centers for Medicare & Medicaid Services would allow states to waive the IMD exclusion, "giving states more flexibility…
An often dismissed option in the struggle to address opioid addiction is the use of medical marijuana. Though usage of the cannabis plant remains controversial in the United States, several studies indicate it may have value in addressing opioid addiction,…
Update: On Wednesday, October 24, 2018, President Trump officially signed the Opioid Crisis Response Act into law. Monday evening, September 17, the United States Senate passed the Opioid Crisis Response Act of 2018, a legislative package of more than 70 bills…
skip to Main Content